Please login to the form below

Not currently logged in
Email:
Password:

FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19

In Europe, the EMA will review a Marketing Authorisation Application for the antibody cocktail

Regeneron HQ

Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for priority review of REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalised patients and as prophylaxis in certain individuals.

The FDA has set a target action date of 13 April 2022 and plans to hold an advisory committee meeting to discuss the application before that date.

The BLA is supported by two positive phase 3 trials involving more than 6,000 patients that evaluated the efficacy and safety of REGEN-COV to treat non-hospitalised patients already infected with SARS-CoV-2, and to prevent symptomatic infection in asymptomatic household contacts of SARS-CoV-2 infected individuals (both uninfected and infected contacts).

A second BLA submission focusing on the treatment of patients hospitalised due to COVID-19 is expected to be submitted later this year.

In Europe, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application for review of the same antibody cocktail, known as Ronapreve in the EU, for use in certain people either as a treatment in infected non-hospitalised patients or as prophylaxis.

Earlier this year in May, detailed results from a phase 3 trial found that REGEN-COV significantly reduced the risk of hospitalisation or death by 70%, and also shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19.

The phase 3 trial evaluated REGEN-COV (casirivimab with imdevimab) in 4,567 high-risk outpatients with COVID-19.

All participants in this trial had at least one risk factor for developing severe COVID-19, including chronic lung disease, obesity, cardiovascular disease or were at least 50 years of age.

In June, the UK-based RECOVERY trial showed REGEN-COV improved survival in hospitalised COVID-19 patients who lack an immune response to the SARS-CoV-2 virus.

In the US, REGEN-COV has not been approved by the FDA, but is currently authorised for emergency use to treat patients with mild-to-moderate COVID-19 who are at high-risk of severe disease or hospitalisation.

Article by
Iona Everson

15th October 2021

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...